This includes exploring investigational PI3K and AKT inhibitors to target hyperactive signaling in PTEN-deficient cancers, combining these inhibitors with standard therapies or immunotherapy to enhance treatment effectiveness, and using PTEN profiling as a predictive biomarker to guide personalized treatment approaches. Here, PIK3CA is linked to cancer.